Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction
| Autor: | Courtney Crim, Nicholas J. Cowans, Robert D. Brook, Peter M.A. Calverley, Dennis E. Niewoehner, Julie C. Yates, Jørgen Vestbo, Julie A. Anderson, Bartolome R. Celli, David E. Newby, Mark T. Dransfield, Sally Kilbride, Fernando J. Martinez |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine medicine.medical_specialty Chlorobenzenes Critical Care and Intensive Care Medicine Placebo Fluticasone propionate law.invention Pulmonary Disease Chronic Obstructive 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Double-Blind Method Randomized controlled trial Adrenal Cortex Hormones law Forced Expiratory Volume Internal medicine Administration Inhalation medicine Humans Prospective Studies 030212 general & internal medicine Prospective cohort study Benzyl Alcohols Aged COPD business.industry Airway obstruction medicine.disease Confidence interval Bronchodilator Agents Airway Obstruction Androstadienes Treatment Outcome 030228 respiratory system chemistry Anesthesia Female Vilanterol business medicine.drug |
| Zdroj: | American Journal of Respiratory and Critical Care Medicine. 195:881-888 |
| ISSN: | 1535-4970 1073-449X |
| DOI: | 10.1164/rccm.201607-1421oc |
| Popis: | Inhaled corticosteroids have been shown to decrease exacerbations in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Their effects in patients with milder airflow obstruction remain unclear.This was an analysis of exacerbations in the SUMMIT (Study to Understand Mortality and Morbidity) study.In a double-blind, randomized controlled trial, once-daily inhaled placebo, fluticasone furoate (FF; 100 μg), vilanterol (VI; 25 μg), or the combination of FF/VI was administered. The primary outcome was all-cause mortality. Exacerbations of COPD were an additional predefined endpoint. A total of 1,368 centers in 43 countries and 16,485 patients with moderate COPD and heightened cardiovascular risk were included in the study.Compared with placebo, FF/VI reduced the rate of moderate and/or severe exacerbations by 29% (95% confidence interval [CI], 22-35; P 0.001) and the rate of hospitalized exacerbations by 27% (95% CI, 13-39; P 0.001). These relative effects were similar regardless of whether subjects had a history of exacerbation in the year before the study or an FEVPatients with moderate chronic airflow obstruction experienced a reduction in exacerbations with FF/VI compared with placebo, irrespective of a history of exacerbations or baseline FEV |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|